Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × darolutamide × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 23 Salivary Gland Neoplasms 3 Metastatic Castration-resistant Prostate Cancer 2 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Neoplasms 1 Neoplasm Metastasis 1 High-Risk Localized Prostate Cancer 1 Granulosa cell tumor of the ovary 1 Carcinoma, Intraductal, Noninfiltrating 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Cancer Female 1 Biochemically Recurrent Prostate Cancer 1

Interventions

Bevacizumab 45 Gemcitabine 44 Cyclophosphamide 39 Carboplatin 37 Docetaxel 34 Fluorouracil 32 Cisplatin 32 Paclitaxel 31 pembrolizumab 28 Oxaliplatin 25 Radiotherapy 24 Irinotecan 23 Leucovorin 22 Capecitabine 22 Dexamethasone 21 Cetuximab 21 Nivolumab 19 Pemetrexed 18 Drug Therapy 18 Doxorubicin 18 Erlotinib Hydrochloride 17 Trastuzumab 15 Rituximab 15 Prednisone 15 durvalumab 14 atezolizumab 13 Sorafenib 13 fludarabine 12 Lapatinib 12 Everolimus 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03314324 2025-04-17

ODENZA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡